• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

JAK2 JH2荧光偏振分析及与三种小分子形成的复合物的晶体结构

JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.

作者信息

Newton Ana S, Deiana Luca, Puleo David E, Cisneros José A, Cutrona Kara J, Schlessinger Joseph, Jorgensen William L

机构信息

Department of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.

Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.

出版信息

ACS Med Chem Lett. 2017 May 17;8(6):614-617. doi: 10.1021/acsmedchemlett.7b00154. eCollection 2017 Jun 8.

DOI:10.1021/acsmedchemlett.7b00154
PMID:28626520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5467202/
Abstract

A competitive fluorescence polarization (FP) assay is reported for determining binding affinities of probe molecules with the pseudokinase JAK2 JH2 allosteric site. The syntheses of the fluorescent and used in the assay are reported as well as results for 10 compounds, including JNJ7706621, NVP-BSK805, and filgotinib (GLPG0634). X-ray crystal structures of JAK2 JH2 in complex with NVP-BSK805, filgotinib, and diaminopyrimidine elucidate the binding poses.

摘要

报道了一种用于测定探针分子与假激酶JAK2 JH2变构位点结合亲和力的竞争性荧光偏振(FP)测定法。还报道了该测定法中使用的荧光团的合成以及10种化合物的结果,包括JNJ7706621、NVP-BSK805和非戈替尼(GLPG0634)。JAK2 JH2与NVP-BSK805、非戈替尼和二氨基嘧啶复合物的X射线晶体结构阐明了结合模式。

相似文献

1
JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.JAK2 JH2荧光偏振分析及与三种小分子形成的复合物的晶体结构
ACS Med Chem Lett. 2017 May 17;8(6):614-617. doi: 10.1021/acsmedchemlett.7b00154. eCollection 2017 Jun 8.
2
Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant.吲哚氧基三嗪作为JAK2 JH2假激酶结构域及其V617F变体的结合分子。
Tetrahedron Lett. 2021 Aug 3;77. doi: 10.1016/j.tetlet.2021.153248. Epub 2021 Jul 2.
3
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.从头建模和实验评估 Janus 激酶 2(JAK2)激酶-假激酶复合物结构。
PLoS Comput Biol. 2013 Apr;9(4):e1003022. doi: 10.1371/journal.pcbi.1003022. Epub 2013 Apr 4.
4
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.JAK2假激酶结构域新型小分子配体的鉴定
Pharmaceuticals (Basel). 2023 Jan 4;16(1):75. doi: 10.3390/ph16010075.
5
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.选择性 Janus 激酶 2(JAK2)假激酶配体,具有二氨基三唑核心。
J Med Chem. 2020 May 28;63(10):5324-5340. doi: 10.1021/acs.jmedchem.0c00192. Epub 2020 May 8.
6
Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.使用收敛设计策略将假虚拟筛选命中转化为选择性JAK2 JH2结构域结合剂
ACS Med Chem Lett. 2022 Apr 21;13(5):819-826. doi: 10.1021/acsmedchemlett.2c00051. eCollection 2022 May 12.
7
Covalent Modification of the JH2 Domain of Janus Kinase 2.Janus激酶2的JH2结构域的共价修饰
ACS Med Chem Lett. 2022 Oct 24;13(11):1819-1826. doi: 10.1021/acsmedchemlett.2c00414. eCollection 2022 Nov 10.
8
The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine.JAK2抑制剂CEP-33779和NVP-BSK805具有较高的P-糖蛋白抑制活性,并使耐药癌细胞对长春新碱敏感。
Biochem Biophys Res Commun. 2017 Sep 2;490(4):1176-1182. doi: 10.1016/j.bbrc.2017.06.178. Epub 2017 Jun 29.
9
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.ATP与JAK2假激酶结构域的结合对于致病性激活至关重要。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.
10
New insights into the structure and function of the pseudokinase domain in JAK2.新型伪激酶结构域在 JAK2 中的结构与功能的深入研究。
Biochem Soc Trans. 2013 Aug;41(4):1002-7. doi: 10.1042/BST20130005.

引用本文的文献

1
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.JAK2假激酶结构域新型小分子配体的鉴定
Pharmaceuticals (Basel). 2023 Jan 4;16(1):75. doi: 10.3390/ph16010075.
2
Covalent Modification of the JH2 Domain of Janus Kinase 2.Janus激酶2的JH2结构域的共价修饰
ACS Med Chem Lett. 2022 Oct 24;13(11):1819-1826. doi: 10.1021/acsmedchemlett.2c00414. eCollection 2022 Nov 10.
3
Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.强效、选择性和细胞渗透性假激酶结构域配体对 JAK2 的调节作用的新见解。
J Med Chem. 2022 Jun 23;65(12):8380-8400. doi: 10.1021/acs.jmedchem.2c00283. Epub 2022 Jun 2.
4
A Comprehensive Overview of Globally Approved JAK Inhibitors.全球获批的JAK抑制剂综合概述
Pharmaceutics. 2022 May 6;14(5):1001. doi: 10.3390/pharmaceutics14051001.
5
Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.使用收敛设计策略将假虚拟筛选命中转化为选择性JAK2 JH2结构域结合剂
ACS Med Chem Lett. 2022 Apr 21;13(5):819-826. doi: 10.1021/acsmedchemlett.2c00051. eCollection 2022 May 12.
6
Diverse saturated heterocycles from a hydroacylation/conjugate addition cascade.通过氢酰化/共轭加成串联反应得到的多种饱和杂环化合物。
Chem Sci. 2022 Jan 19;13(5):1504-1511. doi: 10.1039/d1sc06900d. eCollection 2022 Feb 2.
7
Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant.吲哚氧基三嗪作为JAK2 JH2假激酶结构域及其V617F变体的结合分子。
Tetrahedron Lett. 2021 Aug 3;77. doi: 10.1016/j.tetlet.2021.153248. Epub 2021 Jul 2.
8
Role of water in the determination of protonation states of titratable residues.水在确定可滴定残基质子化状态中的作用。
J Mol Model. 2021 Jan 31;27(2):61. doi: 10.1007/s00894-021-04677-5.
9
Metadynamics as a Postprocessing Method for Virtual Screening with Application to the Pseudokinase Domain of JAK2.元动力学作为虚拟筛选的后处理方法及其在 JAK2 假激酶结构域中的应用。
J Chem Inf Model. 2020 Sep 28;60(9):4403-4415. doi: 10.1021/acs.jcim.0c00276. Epub 2020 May 27.
10
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.选择性 Janus 激酶 2(JAK2)假激酶配体,具有二氨基三唑核心。
J Med Chem. 2020 May 28;63(10):5324-5340. doi: 10.1021/acs.jmedchem.0c00192. Epub 2020 May 8.

本文引用的文献

1
Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.JAK2假激酶结构域小分子结合剂的鉴定与表征
ACS Med Chem Lett. 2017 May 17;8(6):618-621. doi: 10.1021/acsmedchemlett.7b00153. eCollection 2017 Jun 8.
2
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.ATP与JAK2假激酶结构域的结合对于致病性激活至关重要。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.
3
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.三唑并吡啶类作为选择性 JAK1 抑制剂:从苗头化合物的确立到 GLPG0634。
J Med Chem. 2014 Nov 26;57(22):9323-42. doi: 10.1021/jm501262q. Epub 2014 Nov 17.
4
The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains.JH2结构域和SH2-JH2连接区调节JAK2活性:野生型和V617F突变激酶结构域的详细动力学分析。
Biochim Biophys Acta. 2014 Oct;1844(10):1835-41. doi: 10.1016/j.bbapap.2014.07.003. Epub 2014 Aug 7.
5
New insights into the structure and function of the pseudokinase domain in JAK2.新型伪激酶结构域在 JAK2 中的结构与功能的深入研究。
Biochem Soc Trans. 2013 Aug;41(4):1002-7. doi: 10.1042/BST20130005.
6
Fluorescence polarization assays in small molecule screening.小分子筛选中的荧光偏振测定法。
Expert Opin Drug Discov. 2011 Jan;6(1):17-32. doi: 10.1517/17460441.2011.537322.
7
Companies hope for kinase inhibitor JAKpot.各公司对激酶抑制剂JAKpot寄予厚望。
Nat Rev Drug Discov. 2011 Sep 30;10(10):717-8. doi: 10.1038/nrd3571.
8
Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.强效且选择性抑制 JAK2 抑制剂 NVP-BSK805 所致红细胞增多症。
Mol Cancer Ther. 2010 Jul;9(7):1945-55. doi: 10.1158/1535-7163.MCT-10-0053. Epub 2010 Jun 29.
9
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.利用结构信息和化学遗传学开发 Janus 激酶抑制剂的前景。
J Cell Mol Med. 2010 Mar;14(3):504-27. doi: 10.1111/j.1582-4934.2010.01018.x. Epub 2010 Jan 28.
10
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity.用于分析JAK2(V617F)活性的高效蛋白质底物的表征
Exp Hematol. 2007 Nov;35(11):1624-32. doi: 10.1016/j.exphem.2007.07.003. Epub 2007 Aug 30.